pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
SHR-1210
Phase 3 · small molecule · Locally Advanced or Metastatic and Unresectable HCC
SHR-1210 for Locally Advanced or Metastatic and Unresectable HCC is a Phase 3 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).
Internal code SHR-1210-III-310
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jian Li
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Locally Advanced or Metastatic and Unresectable HCC
- Status
- completed
- Trials
- 1